MC2 Therapeutics Acquires Option to Phase 2 Oral Drug Candidate for Hidradenitis Suppurativa and Other Indications
POSTED: September 25, 2023
- Option to exclusively license the rights to develop, manufacture and commercialize “RGRN-305” for all human indications, incl. oral treatment of Hidradenitis Suppurativa (“HS”)
- RGRN-305 is a new chemical entity having a ...
READ FULL ARTICLE >
MC2 Therapeutics and Huadong Announce License, Development and Commercialization Agreement for Wynzora® Cream in Greater China
POSTED: August 31, 2023
Copenhagen, Denmark and Hangzhou, China, August 31st, 2023 – MC2 Therapeutics, Ltd (“MC2”), a wholly owned subsidiary of MC2 Therapeutics A/S and Hangzhou Zhongmei Huadong Pharmaceutical Co (“Huadong”), a wholly ...
READ FULL ARTICLE >
MC2 Therapeutics to present at BIO CEO & Investor Conference 2023
POSTED: January 31, 2023
Copenhagen, January 31st, 2023 – MC2 Therapeutics A/S, a commercial stage pharmaceutical company, engaged in research in skin biology and development of novel treatment paradigms for autoimmune and chronic inflammatory ...
READ FULL ARTICLE >
